NVIC Articles

Disease-Vaccine-Landing-Page

Disease-Vaccine-Landing-Page

Latest articles

Browse Articles

Placeholder image
Page

On July 17, 2023, the FDA approved the drug nirsevimab under the trade name Beyfortus, a monoclonal antibody, for the prevention of RSV in infants and children up to 24...

Placeholder image
Page

In pre-licensing clinical trials, the most frequently reported side effect was pain at the injection site. Within four days of receipt of the vaccine, the most commonly reported systemic adverse...

Placeholder image
Page

During clinical trials for ABRYSVO, in persons 60 years of age and older, the most commonly reported adverse events included swelling, pain, and redness at the injection site, fatigue, headache,...

Placeholder image
Page

An analysis conducted for The Health 202 in the fall of 2022 reported a higher mortality rate in COVID-19 vaccinated individuals than those who were unvaccinated. According to the study,...

Placeholder image
Page

In the fall of 2022, the FDA issued EUAs to both Pfizer-BioNTech and Moderna for bivalent booster dose of COVID-19 mRNA vaccine, containing the original Wuhan strain and the BA.4...

Placeholder image
Page

On October 29, 2021, the FDA authorized the use of a 10mcg dose of Pfizer-BioNTech COVID-19 mRNA vaccine in children 5 through 11 years of age. The vaccine was authorized...

Placeholder image
Page

In June 2023, the FDA’s VRBPAC met and voted to recommend that all COVID-19 vaccines manufactured for use in the United States be updated to target the Omicron XBB strain,...

Placeholder image
Page

An article published on September 30, 2021 in the European Journal of Epidemiology reported that vaccination has had no impact on COVID-19 rates. According to the published data that looked...

Placeholder image
Page

The B.1.1.529 variant (Omicron), which was initially identified in early November 2021 in South Africa, was labeled a Variant of Concern by WHO on November 26, 2021. According to WHO,...

Placeholder image
Page

In February 2021, the CDC stated that currently available mRNA COVID-19 vaccines would likely offer fully vaccinated individuals at least three months of vaccine-acquired immunity. In their quarantine guidance released...

Topics
Select disease / vaccine